The global non-animal alternative testing market is envisioned to garner $29,390.3 million by 2030, growing from $9,806.6 million in 2021 at a CAGR of 13.48% from 2022 to 2030.
Animal testing has been common across generations to establish whether particular chemicals are safe for use by humans and/or the environment. However, this primary method raises a number of issues about the animals involved and is also widely seen as inhumane. This forced medical professionals and researchers everywhere to concentrate their efforts and adopt fresh approaches to understand disease pathophysiology in people. Recent experiments are guiding scientists toward non-animal testing and disease study techniques that are much more applicable to humans.
A large increase in the demand for pharmaceuticals and treatments among people as a result of increasing prevalence of various illnesses around the world is the primary reason driving expansion of the global non-animal alternative testing market. Additionally, increased focus of market players on the development of novel products such as artificial organs, to meet the rising demand for cutting-edge drug testing solutions for a variety of illnesses, such as diabetes, is anticipated to open doors for the market growth in the anticipated period. However, it is anticipated that throughout the projection period, lack of awareness among drug developers regarding the use and advantages of non-animal alternative testing is projected to restrain the market growth.
It has been demonstrated that the emergence of the COVID-19 pandemic had a positive impact on the development of the non-animal alternative testing industry. As the COVID-19 pandemic has had such a terrible impact on people's health and welfare globally, patients now take extra care and precautions to stay safe from viral infections. Due to the high rate of coronavirus transmission and prevalence of serious symptoms, many researchers have forbidden themselves from working in a wet laboratory and making any sort of contact with either humans or animals during pre-clinical testing of the drugs. As a result, the use of less invasive testing techniques has increased such as microarrays, which do not involve using animals.
The key players profiled in this report include VITROCELL Systems GmbH, Evotec SE, Biovit, MB Research Laboratories, Emulate, Inc., TARA Biosystems, Inc., Bio-Rad Laboratories, Inc., Abbott, Hurel Corporation, and TissUse GmbH.
Animal testing has been common across generations to establish whether particular chemicals are safe for use by humans and/or the environment. However, this primary method raises a number of issues about the animals involved and is also widely seen as inhumane. This forced medical professionals and researchers everywhere to concentrate their efforts and adopt fresh approaches to understand disease pathophysiology in people. Recent experiments are guiding scientists toward non-animal testing and disease study techniques that are much more applicable to humans.
A large increase in the demand for pharmaceuticals and treatments among people as a result of increasing prevalence of various illnesses around the world is the primary reason driving expansion of the global non-animal alternative testing market. Additionally, increased focus of market players on the development of novel products such as artificial organs, to meet the rising demand for cutting-edge drug testing solutions for a variety of illnesses, such as diabetes, is anticipated to open doors for the market growth in the anticipated period. However, it is anticipated that throughout the projection period, lack of awareness among drug developers regarding the use and advantages of non-animal alternative testing is projected to restrain the market growth.
It has been demonstrated that the emergence of the COVID-19 pandemic had a positive impact on the development of the non-animal alternative testing industry. As the COVID-19 pandemic has had such a terrible impact on people's health and welfare globally, patients now take extra care and precautions to stay safe from viral infections. Due to the high rate of coronavirus transmission and prevalence of serious symptoms, many researchers have forbidden themselves from working in a wet laboratory and making any sort of contact with either humans or animals during pre-clinical testing of the drugs. As a result, the use of less invasive testing techniques has increased such as microarrays, which do not involve using animals.
The key players profiled in this report include VITROCELL Systems GmbH, Evotec SE, Biovit, MB Research Laboratories, Emulate, Inc., TARA Biosystems, Inc., Bio-Rad Laboratories, Inc., Abbott, Hurel Corporation, and TissUse GmbH.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the non-animal alternative testing market analysis from 2021 to 2030 to identify the prevailing non-animal alternative testing market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the non-animal alternative testing market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global non-animal alternative testing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Technology
- Cell Culture
- High Throughput
- Molecular Imaging
- OMIC Technology
By Method
- Cellular Assay
- Biochemical Assay
- In-silico
- Ex-vivo
By End User
- Pharmaceutical Industry
- Cosmetics Household Products
- Diagnostics
- Chemicals Industry
- Food Industry
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA
Key Market Players
- VITROCELL Systems GmbH
- Evotec SE
- Biovit
- MB Research Laboratories
- Emulate, Inc.
- TARA Biosystems, Inc.
- Bio-Rad Laboratories, Inc.
- Abbott
- Hurel Corporation
- TissUse GmbH
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY
CHAPTER 5: NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD
CHAPTER 6: NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER
CHAPTER 7: NON-ANIMAL ALTERNATIVE TESTING MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Non-Animal Alternative Testing Market," the non-animal alternative testing market size was $9.8 billion in 2021, and is estimated to reach $29.4 billion by 2030, growing at a CAGR of 13.5% from 2022 to 2030.The most recent methods, known as non-animal alternatives, are frequently utilized in scientific research projects for a variety of purposes, including chemical testing, medicine development, and cosmetic product testing. The use of non-animal alternatives testing involves a wide range of technologies, including cell culture, high throughput, and omic.
In the anticipated time frame, the market share rise of non-animal alternative testing is anticipated to be driven by the rapidly rising cases of chronic diseases including viral diseases among millennial as a result of factors such as bad food eating habits. Worldwide, a great number of people struggle with various illnesses such as high blood pressure. Several times, the virus develops a particular drug resistance, making it impossible to treat the patient's illness with any medication. This has significantly raised the market demand for new medications. Future market growth for non-animal alternative testing is projected to be boosted by this factor. Additionally, several nations forbid using animals in the pre-clinical testing of a variety of pharmaceuticals and cosmetics. In addition, evolving ethical concern related to the use of animals in product testing are anticipated to speed up the market expansion.
Non-animal alternative testing is a new and developing technology, and few scientists are familiar with how it should be used. The market share expansion of non-animal alternative testing is therefore expected to be constrained by this factor in the future.
Future market share growth for non-animal alternative testing is anticipated to be fueled by improvements in the currently available non-animal alternative testing products and also with the introduction of new products in market. In order to address the rising needs for cutting-edge drug testing solutions for various ailments such as diabetes, major industry players in the non-animal alternative testing market have started concentrating on creating and releasing new products such as artificial organs. These elements are projected to fuel the expansion of the non-animal alternative testing market in the coming years.
The global non-animal alternative testing market share is segmented based on technology, method, end-user, and region. By technology, it is classified into cell culture technology, high throughput technology, molecular imaging, and omic technology. By method, it is classified into cellular assay, biochemical assay, in silico, and ex-vivo. By end-user, it is classified into pharmaceutical industry, cosmetics & household products, diagnostics, chemical industry, and food industry. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in the non-animal alternative testing industry report include VITROCELL Systems GmbH, Evotec SE, Biovit, MB Research Laboratories, Emulate, Inc., TARA Biosystems, Inc., Bio-Rad Laboratories, Inc., Abbott, Hurel Corporation, and TissUse GmbH.
The report offers a comprehensive analysis of the global non-animal alternative testing market trends by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards growth of the market. The report also sheds light on the present scenario and upcoming trends & developments that are contributing to growth of the market. Moreover, restraints and challenges that hold power to obstruct the market growth are also profiled in the report along with the Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market. The report provides the global non-animal alternative testing market analysis from 2021 - 2030 and the global non-animal alternative testing market forecast from 2022 - 2030.
Impact of COVID-19 on the Global Non-animal Alternative Testing Industry
- The COVID-19 pandemic has shown a favorable effect on the expansion of the non-animal alternative testing sector
- Patients are now being extremely cautious of viral infections and its severe symptoms due to the COVID-19 pandemic which had a very negative influence on peoples' health and welfare worldwide
- Many researchers have banned themselves from working in a wet laboratory and making any form of contact with either humans or animals during pre-clinical testing of the medications due to the high rate of coronavirus transmission and prevalence of significant symptoms. This has led to a rise in the usage of less invasive testing methods such as microarrays that do not utilize animals.
- Additionally, with the number of COVID-19 cases increasing globally, there is a greater need for an effective anti-pandemic medicine, which has further prompted researchers and scientists to utilize non-animal alternative testing to expedite their research efforts. This factor has helped the market to thrive during the pandemic time.
Key Findings of the Study
- Based on technology, the cell culture technology sub-segment emerged as the global leader in 2020 and the omic technology sub-segment is anticipated to be the fastest growing sub-segment during the forecast period
- Based on method, the cellular assay sub-segment emerged as the global leader in 2020 and the ex-vivo sub-segment is anticipated to be the fastest growing sub-segment during the forecast period
- Based on end-user, the pharmaceutical industry sub-segment emerged as the global leader in 2020 and the chemical industry sub-segment is predicted to show the fastest growth in the upcoming years
- Based on region, the North America market registered the highest market share in 2020 and Asia-Pacific market is predicted to show the fastest growth in the upcoming years
Companies Mentioned
- Vitrocell Systems GmbH
- Evotec Se
- Biovit
- Mb Research Laboratories
- Emulate, Inc.
- Tara Biosystems, Inc.
- Bio-Rad Laboratories, Inc.
- Abbott
- Hurel Corporation
- Tissuse Gmbh
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
